Health claim evaluation on grape seed extract and maintenance of normal blood pressure published by EFSA
Aug 31, 2021
On August 9, EFSA published an evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: MegaNaturalâBP grape seed extract and maintenance of normal blood pressure.
The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. MegaNatural娉BP, a grape seed extract standardised for total phenolics, gallic acid and the catechin and epicatechin content, is sufficiently characterised. The proposed claimed effect, maintenance of normal blood pressure (BP), is a beneficial physiological effect. Among the two human intervention studies provided from which conclusions could be drawn, one showed an effect of MegaNatural娉BP (300 mg/day) on BP in adults with normal and high normal BP when consumed daily for 6 weeks, whereas the second study did not show an effect of MegaNatural娉BP at the same daily dose consumed for 8 weeks in adults with normal and high normal blood pressure or stage 1 hypertension. The evidence provided did not establish a plausible mechanism by which the food could exert the claimed effect in vivo in humans. The evidence provided is insufficient to establish a cause and effect relationship between the consumption of MegaNatural娉BP and maintenance of normal blood pressure.
For further information (in English), click on the Link
Optimizing the Relationship between Regulation and Innovation in Dietary Supplements: A Case Study of Food with Function Claims in Japan
Japan
Jan 19, 2023
China - Food and medicine continuum’ in the East and West: Old tradition and current regulation
China
Dec 22, 2022
Food Labeling Systems in Japan: Nutrition and Health Claims
Japan
Dec 08, 2022
Function and disease risk reduction claims
Thailand
Nov 24, 2022
FDA warns companies of using claims to treat cardiovascular disease
USA
Nov 17, 2022
A Critical Appraisal of the Separation Protocols Proposed for the Implementation of the Health Claim on “Olive Oil Polyphenols” (EC Regulation 432/2012)
European Union
Nov 14, 2022
Health claims on foods
Thailand
Oct 28, 2022
South Korea/USA/EU - CODEX Labelling Standard for Reduction of Disease Risk Claim and the Status in other countries
South Korea
Oct 10, 2022
Label compliance for ingredient verification: regulations, approaches, and trends for testing botanical products marketed for “immune health” in the United States
USA
Sep 27, 2022
Survey on non-compliant health claims in dietary supplements
France
Sep 26, 2022
Nutrition and health claims in the European Union in 2022
European Union
Sep 08, 2022
Amendments on the list of claims for edible vegetable oils
India
Sep 05, 2022
Guidelines on claims for health products
Indonesia
Aug 30, 2022
Guidelines for health supplement claims
Indonesia
Aug 29, 2022
Regulation on restriction of eucalyptus leaves and its extracts
Taiwan
Aug 23, 2022
Expertise in countries
- Argentina
- Australia
- Brazil
- Brunei
- Cambodia
- Canada
- Chile
- Colombia
- Ecuador
- Egypt
- European Union
- India
- Indonesia
- Laos
- Japan
- Malaysia
- Mexico
- Myanmar
- New Zealand
- Nigeria
- Paraguay
- Philippines
- Peru
- Russia
- Saudi Arabia
- Singapore
- South Africa
- South Korea
- Switzerland
- Thailand
- Türkiye
- UAE
- UK
- Ukraine
- Uruguay
- USA
- Vietnam
